Lexington, KY, USA, 29th December 2025, FinanceWire … Read More
ETFs
Nasus Pharma Receives $19 Price Target and ‘Market Outperform’ Rating From Citizens Analyst
WSW, NY, 18th December 2025, FinanceWire … Read More
Nuvectis Pharma’s New Phase 1b Trial Targets a Major Lung Cancer Bottleneck (NASDAQ: NVCT)
WSW, NY, 17th December 2025, FinanceWire … Read More
Silexion Therapeutics Receives $6 Price Target and Buy Rating From Litchfield Hills Research (NASDAQ: SLXN)
WSW, NY, 15th December 2025, FinanceWire … Read More
InterCure May Be Uniquely Positioned as Trump’s Cannabis Rescheduling Returns to Headlines (NASDAQ: INCR)
WSW, NY, 12th December 2025, FinanceWire … Read More
The Great ETF Mirage: New Study by DayTrading.com Shows Thematic ETF Risks
London, United Kingdom, 12th December 2025, FinanceWire … Read More
Inspira Technologies May be Perfectly Positioned as Flu Cases Increase and Respiratory Complexity Grows (NASDAQ: IINN)
WSW, NY, 11th December 2025, FinanceWire … Read More
Alpha Tau Medical Just Treated Its First Brain Tumor Patient – and It Could Mark an Inflection Point for the Company (NASDAQ: DRTS)
WSW, NY, 10th December 2025, FinanceWire … Read More
CentFX Announces Participation in iFX Expo 2026 as Silver Sponsor, Showcasing New Fintech Innovations
Dubai, United Arab Emirates, 10th December 2025, FinanceWire … Read More
PolyPid Clears a Key FDA Milestone, Reducing Regulatory Risk Ahead of Its Planned NDA Filing (NASDAQ: PYPD)
WSW, NY, 5th December 2025, FinanceWire … Read More